Urinary excretion of TXB2 after angiotensin converting enzyme inhibition in hypertensive patients.
Urinary excretion of thromboxane B2 (TXB2), a stable metabolite of thromboxane A2 (TXA2), was measured by radioimmunoassay in 7 essential hypertensive patients before and after a converting enzyme inhibitor, SQ 14225, administration. When a single oral dose of SQ 14225 (50mg) was given to 7 patients with essential hypertension, urinary excretion of TXB2 was increased significantly (from 58.9 +/- 18.1 to 116.1 +/- 20.7 pg/min, mean +/- SE, P less than 0.02) with simultaneous increase in plasma renin activity, urine volume, urinary sodium, urinary potassium and urinary excretion of PGE (from 58.8 +/- 12.8 to 135.1 +/- 30.0 pg/min, mean +/- SE, P less than 0.05). These results indicate that SQ 14225 stimulates vasoconstricting TXA2 production as well as vasodilating PGE production.
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D007700:Kinetics; D011188:Potassium / Q000652:urine; D011458:Prostaglandins E / Q000652:urine; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D013929:Thromboxane B2 / Q000652:urine*
D000806:Angiotensin-Converting Enzyme Inhibitors; D011458:Prostaglandins E; D013929:Thromboxane B2; D002216:Captopril; D012964:Sodium; D012083:Renin; D011188:Potassium